Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diquafosol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 known ✓ | P41231 | 12/20 | 1.00 |
| ▸ | P2RY4 known ✓ | P51582 | 7/20 | 1.00 |
| ▸ | P2RY6 known ✓ | Q15077 | 6/20 | 1.00 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15082674 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 | |
| Diquafosol SCHEMBL22889034 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 | |
| Diquafosol SCHEMBL21415941 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL15082662 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 | |
| Diquafosol SCHEMBL24414702 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 | |
| Diquafosol SCHEMBL22336797 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 | |
| Diquafosol SCHEMBL24414701 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 | |
| Diquafosol SCHEMBL20642231 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 | |
| Diquafosol SCHEMBL22198897 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL12714921 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815263-B2 | Method for purifying P1,P4-di(uridine 5′-)tetraphosphate | YAMASA CORPORATION (JP) | 2020-10-27 | — | — | US | disclosed |
| US-20190233462-A1 | METHOD FOR PURIFYING P1,P4-DI(URIDINE 5'-)TETRAPHOSPHATE | YAMASA CORPORATION (JP) | 2019-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233462-A1 | METHOD FOR PURIFYING P1,P4-DI(URIDINE 5'-)TETRAPHOSPHATE | UPP1, UMPS, UGP2 | P2RY2 399/4885P2RY4 158/4885P2RY6 111/4885 |
| US-10815263-B2 | Method for purifying P1,P4-di(uridine 5′-)tetraphosphate | UPP1, UMPS, UGP2 | P2RY2 396/4885P2RY4 156/4885P2RY6 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.